Phase I study of NGR-TNF, a novel vascular targeting agent, in patients with refractory solid tumours (EORTC 16041)

被引：0
|
作者：
Van Herpen, C.
Fiedler, W.
Toma, S.
Marreaud, S.
Van Laarhoven, H.
Lasch, P.
Bogaerts, J.
Heerschap, A.
Bordignon, C.
Punt, C.
机构：
[1] Radboud Univ Nijmegen Med Ctr, Dept Med Oncol, Nijmegen, Netherlands
[2] Univ Hosp Hamburg Eppendorf, Dept Med 2, Hamburg, Germany
[3] Molmed, Milan, Italy
[4] EORTC, Brussels, Belgium
[5] Radboud Univ Nijmegen Med Ctr, Dept Radiol, Nijmegen, Netherlands
来源：
EJC SUPPLEMENTS | 2006年 / 4卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(06)70371-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
366
引用
收藏
页码：113 / 113
页数：1
相关论文
共 50 条
  • [41] A phase II study of NGR-hTNF, a novel vascular targeting agent (VTA), administered as single agent at low dose in pretreated patients (pts) with advanced hepatocellular carcinoma (HCC)
    Citterio, G.
    Santoro, A.
    Scalamogna, R.
    Pressiani, T.
    Gregorc, V.
    Rossoni, G.
    Donadoni, G.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [42] Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), in previously treated patients with hepatocellular carcinoma (HCC)
    Santoro, A.
    Citterio, G.
    Pressiani, T.
    De Braud, F. G.
    Gregorc, V.
    Rossoni, G.
    Donadoni, G.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [43] NGR-hTNF, a vascular targeting agent (VTA), in previously treated patients with malignant pleural mesothelioma (MPM): a phase II study
    Gregorc, V.
    Ceresoli, G. L.
    Zucali, P. A.
    De Braud, F. G.
    Bajetta, E.
    Santoro, A.
    Vigano, M. G.
    Cappio, F. Caligaris
    Lambiase, A.
    Bordignon, C.
    EJC SUPPLEMENTS, 2009, 7 (02): : 509 - 509
  • [44] Safety and anticancer activity of low dose regimen of NGRhTNF, a new vascular targeting agent, in solid advanced malignancies (NGR002 phase I trial)
    Gallo-Stampino, C.
    Rizzardi, G.
    Toma, S.
    Corti, A.
    Scifo, P.
    Citterio, G.
    Gregorc, V.
    Del Maschio, A.
    Caligaris-Capio, F.
    Bordignon, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [45] A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours
    Eskens, F. A. L. M.
    Tresca, P.
    Tosi, D.
    Van Doorn, L.
    Fontaine, H.
    Van der Gaast, A.
    Veyrat-Follet, C.
    Oprea, C.
    Hospitel, M.
    Dieras, V.
    BRITISH JOURNAL OF CANCER, 2014, 110 (09) : 2170 - 2177
  • [46] A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours
    F A L M Eskens
    P Tresca
    D Tosi
    L Van Doorn
    H Fontaine
    A Van der Gaast
    C Veyrat-Follet
    C Oprea
    M Hospitel
    V Dieras
    British Journal of Cancer, 2014, 110 : 2170 - 2177
  • [47] A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours
    Dredge, Keith
    Brennan, Todd V.
    Hammond, Edward
    Lickliter, Jason D.
    Lin, Liwen
    Bampton, Darryn
    Handley, Paul
    Lankesheer, Fleur
    Morrish, Glynn
    Yang, Yiping
    Brown, Michael P.
    Millward, Michael
    BRITISH JOURNAL OF CANCER, 2018, 118 (08) : 1035 - 1041
  • [48] An EORTC-ECSG phase I study of LU 79553 administered every 21 or 42 days in patients with solid tumours
    Awada, A
    Thödtmann, R
    Piccart, MJ
    Wanders, J
    Schrijvers, AHGJ
    Von Broen, IM
    Hanauske, AR
    EUROPEAN JOURNAL OF CANCER, 2003, 39 (06) : 742 - 747
  • [49] A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours
    Keith Dredge
    Todd V. Brennan
    Edward Hammond
    Jason D. Lickliter
    Liwen Lin
    Darryn Bampton
    Paul Handley
    Fleur Lankesheer
    Glynn Morrish
    Yiping Yang
    Michael P. Brown
    Michael Millward
    British Journal of Cancer, 2018, 118 : 1035 - 1041
  • [50] A phase I dose-escalation trial of ZD6126, a novel vascular targeting agent, in patients with cancer refractory to other treatments.
    Lorusso, PM
    Gadgeel, S
    Wozniak, A
    Barge, A
    McKinley, M
    McKinlay, T
    Swaisland, A
    Wheeler, C
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3660S - 3660S
12345